Zyversa Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
ZyVersa Therapeutics reports a net loss of $1.8 million for Q1 2026, with significant cash burn and ongoing need for financing.
OQB
ZyVersa Therapeutics reported a significant net loss and an $18.6 million impairment charge, raising substantial doubt about its ability to continue as a going concern following its Nasdaq delisting.
OQB
ZyVersa Therapeutics reports significant losses and a going concern warning, with its common stock delisted from Nasdaq and now trading on OTCQB.
OQB
ZyVersa Therapeutics reports a net loss of $2.3 million for Q1 2025, with ongoing focus on developing its lead drug candidates VAR 200 and IC 100.
OQB
ZyVersa Therapeutics reported its Q3 2024 financial results, showing a net loss and ongoing efforts to secure additional funding.
OQB
10-Q: ZyVersa Therapeutics Reports Q2 2024 Results, Cites Ongoing Losses and Need for Additional Funding
ZyVersa Therapeutics reported a net loss of $5.6 million for the first half of 2024 and highlighted its need for additional financing to continue operations.
OQB
ZyVersa Therapeutics reported a net loss of $2.8 million for the first quarter of 2024, with ongoing efforts to advance their clinical-stage drug candidates.